Senior Physician, Brigham and Women’s Hospital
Professor of Medicine, Harvard Medical School
Director, Noninvasive Cardiology
Brigham and Women’s Hospital
Department of Medicine
Scott D. Solomon, MD is The Edward D. Frohlich Distinguished Chair, Professor of Medicine at Harvard Medical School, Director of Noninvasive Cardiology and Senior Physician at Brigham and Women’s Hospital. He directs the Cardiac Imaging Core Laboratory and the Clinical Trials Endpoints Center at Brigham and Women’s Hospital. He received his A.B. from Williams College and his M.D. from Harvard Medical School.
Dr. Solomon’s research interests have focused on changes in ventricular structure and function following myocardial injury, modifiers of risk and influences of outcome in patients following myocardial infarction and with chronic heart failure, cardiovascular safety of non-cardiovascular therapies, factors that influence the transition from hypertension to heart failure, and heart failure with preserved ejection fraction. He has pioneered the use of cardiac imaging in cardiovascular drug and device development and use of imaging in clinical trials. He and his research group have played a leading role in many international clinical trials in heart failure, hypertension and myocardial infarction, including the SAVE, HEART, VALIANT, CHARM, PEACE, OVERTURE, MADIT- CRT, ALOFT, ALLAY, TREAT, RED-HF, ALTITUDE, FREEDOM, TOPCAT trials. He led the NIH- sponsored Celecoxib Cross-trials Safety Study which directly informed regulatory agencies about the safety of widely used non-steroidal anti-inflammatory agents. He directs the Cardiac Imaging Center for the NHLBI Atherosclerosis Risk in Communities (ARIC) study and Hispanic Community Health Study – Study of Latinos (HCHS-SOL), the two largest NIH cohort studies. He is PI of the NHLBI sponsored INVESTED trial studying the role of inluenza vaccine in preventing morbidity and mortality in high-risk cardiovascular patients.
Dr. Solomon has recently studied the role for angiotensin receptor neprilysin inhibition in heart failure. He served as member of the executive committee for the PARADIGM-HF trial, led the first successful Phase II trial in heart failure with preserved ejection fraction and is currently leading the ongoing PARAGON-HF outcomes trial in HFpEF.
Dr. Solomon leads a research group consisting of 6 faculty members, 8 research fellows and 30 support staff. He currently receives, or has received, extensive research support from the NIH and multiple industry sponsors. He has directed the Harvard Medical School Cardiovascular Clerkship and the Echocardiography training program at Brigham and Women’s Hospital. He has authored more than 400 peer-reviewed articles, reviews and editorials, two textbooks of cardiac imaging, and the Echocardiograph/Imaging sections for the 10th edition of Braunwald’s Heart Disease and 19th edition Harrison’s Principles of Internal Medicine. He is listed by Thomson-Reuters as one of the most highly cited scientists in the past 10 years. He is a Cardiology Section Editor at UpToDate and International Associate Editor at The European Heart Journal.
Source: Website of Brigham and Women’s Hospita